Short report: Infection dynamics of sylvatic dengue virus in a natural primate host, the African green monkey

American Journal of Tropical Medicine and Hygiene

Volumn 91, Issue 4, 2014, Pages 672-676

  Hanley, Kathryn A ^a   Guerbois, Mathilde ^b   Kautz, Tiffany F ^b   Brown, Meredith ^c   Whitehead, Stephen S ^d   Weaver, Scott C ^b   Vasilakis, Nikos ^b   Marx, Preston A ^e  

^a NEW MEXICO STATE UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Banfield Pet Hospital   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NEUTRALIZING ANTIBODY; UREA; VIRUS ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHLOROCEBUS SABAEUS; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; DISEASE COURSE; DISEASE DURATION; ENVELOPE GENE; GASTROINTESTINAL HEMORRHAGE; HEMATOCRIT; HOST CELL; INOCULATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RASH; SEROCONVERSION; STRUCTURAL GENE; UREA NITROGEN BLOOD LEVEL; VIREMIA; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; BIOSYNTHESIS; BLOOD; CHLOROCEBUS AETHIOPS; CLASSIFICATION; DENGUE VIRUS; DISEASE CARRIER; GENETICS; IMMUNOLOGY; MONKEY DISEASE; MOSQUITO; VETERINARY; VIROLOGY;

CERCOPITHECUS AETHIOPS; DENGUE VIRUS; PRIMATES;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CULICIDAE; DENGUE; DENGUE VIRUS; INSECT VECTORS; MALE; MONKEY DISEASES;

EID: 84907710915     PISSN: 00029637     EISSN: 14761645     Source Type: Journal    
DOI: 10.4269/ajtmh.13-0492     Document Type: Article

References (36)

1. Hanley KA, Monath TP, Weaver SC, Rossi SL, Richman RL, Vasilakis N, 2013. Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol 19: 292-311.
2. Kurane I, Ennis FE, 1992. Immunity and immunopathology in dengue virus infections. Semin Immunol 4: 121-127.
3. Sabin AB, 1952. Research on dengue during World War II. Am J Trop Med Hyg 1: 30-50.
4. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, 2007. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
5. Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA, 2014. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis. Virology 452-453: 237-246.
6. Nguyet MN, Duong TH, Trung VT, Nguyen TH, Tran CN, Long VT, Dui le T, Nguyen HL, Farrar JJ, Holmes EC, Rabaa MA, Bryant JE, Nguyen TT, Nguyen HT, Nguyen LT, Pham MP, Nguyen HT, Luong TT, Wills B, Nguyen CV, Wolbers M, Simmons CP, 2013. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci USA 110: 9072-9077.
7. Vasilakis N, Cardosa J, Hanley KA, Holmes EC, Weaver SC, 2011. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat Rev Microbiol 9: 532-541.
8. Monlun E, Zeller H, Traore-Lamizana M, Hervy JP, Adam F, Mondo M, Digoutte JP, 1992. Caracteres cliniques et epidemiologiques de la dengue 2 au Senegal. Med Mal Infect 22: 718-721.
9. Robin Y, Cornet M, Heme G, Le Gonidec G, 1980. Isolement du virus dela dengue au Senegal. Ann Virol 131: 149-154.
10. Saluzzo JF, Cornet M, Adam C, Eyraud M, Digoutte JP, 1986. Dengue 2 in eastern Senegal: serologic survey in simian and human populations. 1974-85. Bull Soc Pathol Exot 79: 313-322.
11. Saluzzo JF, Cornet M, Castagnet P, Rey C, Digoutte JP, 1986. Isolation of dengue 2 and dengue 4 viruses from patients in Senegal. Trans R Soc Trop Med Hyg 80: 5.
12. Carey DE, 1963. Use of a combined complement-fixing antigen to detect arthropod-borne viral infection. Nature 200: 1024-1025.
13. Vasilakis N, Tesh RB, Weaver SC, 2008. Sylvatic dengue virus type 2 activity in humans, Nigeria, 1966. Emerg Infect Dis 14: 502-504.
14. Cardosa J, Ooi MH, Tio PH, Perera D, Holmes EC, Bibi K, Abdul Manap Z, 2009. Dengue virus serotype 2 from a sylvatic lineage isolated from a patient with dengue hemorrhagic fever. PLoS Negl Trop Dis 3: e423.
15. Franco C, Hynes NA, Bouri N, Henderson DA, 2010. The dengue threat to the United States. Biosecur Bioterror 8: 273-276.
16. Althouse BM, Lessler J, Sall AA, Diallo M, Hanley KA, Watts DM, Weaver SC, Cummings DA, 2012. Synchrony of sylvatic dengue isolations: a multi-host, multi-vector SIR model of dengue virus transmission in Senegal. PLoS Negl Trop Dis 6: e1928.
17. Carrara AS, Gonzales G, Ferro C, Tamayo M, Aronson J, Paessler S, Anishchenko M, Boshell J, Weaver SC, 2005. Venezuelan equine encephalitis virus infection of spiny rats. Emerg Infect Dis 11: 663-669.
18. Del Amo J, Llorente F, Figuerola J, Soriguer RC, Moreno AM, Cordioli P, Weissenbock H, Jimenez-Clavero MA, 2014. Experimental infection of house sparrows (Passer domesticus) with West Nile virus isolates of Euro-Mediterranean and North American origins. Vet Res 45: 33.
19. Mandl JN, Akondy R, Lawson B, Kozyr N, Staprans SI, Ahmed R, Feinberg MB, 2011. Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host. J Immunol 186: 6406-6416.
20. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS, 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405-413.
21. Hanley KA, Manlucu LR, Manipon GG, Hanson CT, Whitehead SS, Murphy BR, Blaney JE Jr, 2004. Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 22: 3440-3448.
22. Whitehead SS, Hanley KA, Blaney JE Jr, Gilmore LE, Elkins WR, Murphy BR, 2003. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21: 4307-4316.
23. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, Murphy BR, Karron RA, 2005. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191: 710-718.
24. Vasilakis N, Fokam EB, Hanson CT, Weinberg E, Sall AA, Whitehead SS, Hanley KA, Weaver SC, 2008. Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains. Virology 377: 296-307.
25. Vasilakis N, Shell EJ, Fokam EB, Mason PW, Hanley KA, Estes DM, Weaver SC, 2007. Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology 358: 402-412.
26. Bray M, Men R, Tokimatsu I, Lai CJ, 1998. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. J Virol 72: 1647-1651.
27. Hanley KA, Nelson JT, Schirtzinger EE, Whitehead SS, Hanson CT, 2008. Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus. BMC Ecol 8: 1.
28. Vasilakis N, Durbin AP, da Rosa AP, Munoz-Jordan JL, Tesh RB, Weaver SC, 2008. Antigenic relationships between sylvatic and endemic dengue viruses. Am J Trop Med Hyg 79: 128-132.
29. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS, 2006. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 19: 10-32.
30. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM, 2010. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6: e1000821.
31. Alvarez M, Pavon-Oro A, Rodriguez-Roche R, Bernardo L, Morier L, Sanchez L, Alvarez AM, Guzman MG, 2008. Neutralizing antibody response variation against dengue 3 strains. J Med Virol 80: 1783-1789.
32. Kato F, Ishida Y, Kawagishi T, Kobayashi T, Hishiki T, Miura T, Igarashi T, 2013. Natural infection of cynomolgus monkeys with dengue virus occurs in epidemic cycles in the Philippines. J Gen Virol 94(Pt 10): 2202-2207.
33. Halstead SB, Shotwell H, Casals J, 1973. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 128: 7-14.
34. Liddie S, Goody RJ, Valles R, Lawrence MS, 2010. Clinical chemistry and hematology values in a Caribbean population of African green monkeys. J Med Primatol 39: 389-398.
35. Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, Whitehead S, Natarajan R, Laughlin C, 2010. Report of an NIAID workshop on dengue animal models. Vaccine 28: 4229-4234.
36. Casaco A, Beausoleil I, Gonzalez B, Luaces P, Leon A, Arteaga ME, Prado P, Rodriguez V, Perez A, Guevara G, Bada AM, Ledon N, Fuentes D, Gonzalez C, Hernandez O, Orphee R, Blanco D, Garcia-Osuma M, Ballester-Labrada A, 2010. Hematological, biochemical, respiratory, cardiovascular and electroneurophysiological parameters in African green monkeys (Cercopithecus aethiops sabaeus). Its use in non-clinical toxicological studies. J Med Primatol 39: 177-186.